Vioxx Strategy Aims To Switch Patients Up From OTC To Rx Market
Executive Summary
Merck is looking to move patients out of the over-the-counter analgesic market to the prescription COX-2 inhibitor Vioxx, Merck Human Health-The Americas President David Anstice said at Merck's annual business briefing Dec. 9 in Whitehouse Station, N.J.
You may also be interested in...
Schering Sales Force Reduction Shows “Changing Dynamics” In U.S. Market
Schering-Plough's sales force restructuring is a clear indication that the era of escalating field forces is coming to an end
Schering Sales Force Reduction Shows “Changing Dynamics” In U.S. Market
Schering-Plough's sales force restructuring is a clear indication that the era of escalating field forces is coming to an end
Celebrex Switches Create Approximately 7% of Scripts For Merck Vioxx
Switches from Celebrex to Vioxx accounted for approximately 7% of prescriptions for Merck's COX-2 inhibitor during November.